“…Several protective drugs modulate other independent routes that may alternatively be activated during reperfusion and that are not assigned to the RISK, SAFE or the cGMP/PKC pathways. They can have different types of effects such as such as inhibition of ROS-producing complexes [18,67,134,135,136,137,138,139,140,141,142,143], or may act as anti-apoptotic [144], anti-inflammatory [24,53,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164] and antioxidants agents [165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194], as glucose metabolism enhancers [99,…”